Stage III Lung Cancer Clinical Trial
Official title:
External ValidatIon Trial of Aster: the Need for Surgical Staging After Echo-endoscopic Mediastinal Staging in Clinical N2/3 Lung Cancer
As the use of endoscopic ultrasonography for mediastinal diagnosis and/or staging is widely spread in Belgium, the investigators aimed to determine the number of mediastinoscopies needed to detect one additional mediastinal lymph node invasion during routine clinical practice in the staging of potentially resectable clinical stage III non-small cell lung cancer.
Background : The observation made by the ASTER investigators might be criticized as all
procedures were performed in highly experienced centers. To date, the number of
mediastinoscopies needed to detect one additional N2/3 disease in the routine clinical
practice of chest physician performing endosonography for mediastinal staging is unknown.
The investigators therefore seek to answer whether a negative endosonography should
routinely be followed by mediastinoscopy in day to day clinical practice.
Aim : As the use of endoscopic ultrasonography for mediastinal diagnosis and/or staging is
widely spread in Belgium, the investigators aimed to determine the number of
mediastinoscopies needed to detect one additional mediastinal lymph node invasion during
routine clinical practice.
Setting : centers in Belgium with EBUS-TBNA and/or EUS-FNA experience in at least 20
patients agreed to participate and will include their patients.
Design : Prospective national observational multicenter study. All patients with clinical
N2/3 disease based on CT and/or PET requiring invasive mediastinal staging will primarily
undergo invasive mediastinal staging with endosonography (EBUS +/- EUS). A subsequent
cervical mediastinoscopy will be performed in case no mediastinal lymph node involvement was
found with endosonography. Local surgeons perform these procedures according to their
institutional practice. Thoracotomy with mediastinal lymph node dissection will be the gold
standard for invasive mediastinal staging, in case no mediastinal lymph node metastases were
found during clinical staging including endosonography and mediastinoscopy.
Patients : The study will include 255 patients, based on the calculation of 15 consecutive
patients in each participating center, in order to validate the ASTER data.
Primary endpoint : The number of mediastinoscopies needed to detect one additional N2/3.
Secondary endpoints : The number of mediastinal lymph nodes stations sampled with
endosonography ; the median size of largest mediastinal lymph node sampled; characteristics
of mediastinal nodal disease missed by endosonography.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00579215 -
Lung Cancer Informational Study (LCIS)
|
N/A | |
Suspended |
NCT05501665 -
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT06140407 -
Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer
|
Phase 2 | |
Not yet recruiting |
NCT04985357 -
Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
|
||
Not yet recruiting |
NCT06383988 -
A Web-based Program to Help Caregivers of Lung Patients Learn About Available Supportive Care Resources
|
N/A | |
Recruiting |
NCT05641870 -
Molecular Profiling and Dynamic Changes of ctDNA in Unresectable Locally Advanced NSCLC
|
||
Completed |
NCT03112668 -
Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners
|
N/A | |
Completed |
NCT05025748 -
Ask Questions (ASQ):Implementation of a Communication Intervention
|
N/A |